You have a great BATNA and consequently, an aggressive reservation price, and you would be happy if the counterparty matched or barely exceeded your reservation point. In this sense, negotiators "signal" their BATNA. When Onyx Pharmaceuticals, the developer of several cancer drugs for bone marrow cancers was for sale, they felt confident about developing an attractive BATNA. They rejected an offer from Amgen valued at $8.7 billion and entertained offer from Amgen comprtitors, including Pfizer and Novartis. In response, Amgen increased their offer to $10 billion and Onyx rejected it a second time. Amgen increased their offer to $10.4 billion, or $125 per share. At this point, Onyx accepted Amgen's offer, making the purchase one of the five biggest-ever takeovers of a biotechnology company.